The recent FDA approval of the IsoPSA blood test may represent a notable advancement in prostate cancer screening and diagnosis. Developed by Cleveland Diagnostics, the in vitro diagnostic instrument ...

The method had high rates of sensitivity and specificity, although its sensitivity was somewhat lower in cases of localized prostate cancer. The study authors explained that prostate cancer is one of ...

Combined use of systematic and MRI-guided targeted biopsy was better able to detect clinically significant prostate cancers than either method alone, the PAIREDCAP trial found. Among nearly 250 men ...

National Prostate Health Month (NPHM), also known as National Prostate Cancer Awareness Month, is observed every September in the United States (US) by health experts, health advocates, and ...

Conventional imaging methods have limited sensitivity for detecting metastatic prostate cancer. With appropriate, timely treatment vital to survival and quality of life, better imaging has been an ...

Profound Medical (PROF) announced the upcoming launch of its TULSA-AI Volume Reduction module for optimizing the treatment of patients with benign ...

RSNA attendees can find Profound at Booth #3153, South Hall A, for demonstrations of the newly launched TULSA-AI Volume Reduction module, along with case studies and feature upgrades from the pilot ...

Each year, 1 million men in the U.S. undergo biopsies to determine whether they have prostate cancer. The biopsy procedure traditionally has been guided by ultrasound imaging, but this method cannot ...